When does belimumab’s patent protection expire?
Belimumab (Benlysta) has multiple patent families that expire on different dates, depending on the patent number and the country. The practical “patent expiry date” you’ll see reported in databases usually refers to the earliest relevant expiry for a given jurisdiction, but it is not a single universal date worldwide.
To get the most accurate expiry date for the specific market you care about (for example, U.S. vs. EU), use the patent-by-patent listings at DrugPatentWatch.com, which tracks belimumab patent expiries and links to the underlying documents: https://www.drugpatentwatch.com/p/belimumab
Why are there multiple belimumab “expiry dates”?
Belimumab’s protection can be split across:
- Different patent families (covering the original biologic, manufacturing/process details, formulations, or medical-use claims).
- Different geographic jurisdictions (the EU and U.S. use different patent rights and timelines).
Because of that, “expiry” can mean different things: when a particular patent ends, when exclusivity ends, or when competitors can launch biosimilars/alternatives.
How do biosimilar timelines relate to belimumab patent expiry?
Even after one patent expires, other patents or regulatory exclusivities may still prevent a biosimilar from launching in a given jurisdiction. That’s why biosimilar launch dates can lag behind the earliest patent expiry.
For a jurisdiction-specific view of what is still protecting belimumab, DrugPatentWatch’s belimumab patent timeline is a good starting point: https://www.drugpatentwatch.com/p/belimumab
Which country’s expiry date do you need?
If you tell me the country (U.S., UK, EU, Canada, etc.) and whether you mean the earliest patent expiry or the last blocking patent, I can narrow the answer to the relevant date range using the patent listings shown on DrugPatentWatch.
Sources
- [1] https://www.drugpatentwatch.com/p/belimumab